CDA Formulations to Remove Cancer as the Top Killers of Many Asian Countries
DOI:
https://doi.org/10.70818/apjcr.v02i02.028Keywords:
Cancer Stem Cells, Cell Differentiation Agents, Chemo-Surveillance, Methylation Enzymes, Myelodysplastic Syndromes, Progenitor Stem CellsAbstract
The objective of this article is to rectify cancer therapies which are apparently inadequate to result in cancer as the top killer of the people of many Asian countries for a very long time. Cancer therapy had a bad start to rely on toxic chemicals to kill cancer cells (CCs), which was a mistake made at a time when we did not have a complete knowledge of cancer. Cancer stem cells (CSCs) became known in 1997. The discovery of CSCs unraveled a very important issue of cancer. It became evident that, although CSCs constituted only a small subpopulation, these cells were responsible for the initiation of tumor growth and the treatment failure. Thus, the success of cancer therapy depends on the elimination of CSCs. Our studies on abnormal methylation enzymes (MEs), chemo-surveillance, wound healing and cell differentiation agent (CDA) formulations are very closely related to the issue of CSCs. Thus, we are in a unique position to offer the best solution of CSCs. Cancer evolves due to wound unhealing. Chemo-surveillance is the creation of the nature to ensure perfection of wound healing. Chemo-surveillance is specifically destroyed in cancer patients. Restoration of chemo-surveillance offers excellent therapy of cancer. CDA-2 was a preparation of wound healing metabolites purified from urine which has been approved by the Chinese FDA for the therapy of cancer and myelodysplastic syndromes (MDSs). MDSs are diseases attributable entirely to CSCs. CDA-2 was demonstrably the best drug for the therapy of MDSs. CDA formulations are the creation of the nature to remove cancer as the top killer of the people of Asian countries.
References
1. Liau MC, Craig CL, Baker LL. Cytotoxic agents can cure cancer, but can also kill cancer patients. Int J Clin Oncol Cancer Res. 2025;10(1):27-35.
2. Liau MC, Craig CL, Baker LL. Tumor shrinkage can be a promising diagnosis toward remission or can also be an ominous diagnosis toward fatality. J Cancer Res Rev Rep. 2024;6(6):1-8.
3. Liau MC, Fruehauf JP. It has been half a century since President Nixon declared war on cancer: Destabilization of abnormal methylation enzymes has the blessing of nature to win the war on cancer. Adv Complement Alt Med. 2020;6(1):538-539.
4. Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. Int Res J Oncol. 2022;6(3):8-20.
5. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
6. Herman PC, Huber SL, Heachen C. Metastatic cancer stem cells: A new target for anti-cancer therapy? Cell Cycle. 2008;7(2):188-193.
7. Zhou S, Schuetz JD, Bunting KD, Colapietro AM. The ABC transporter Bcrp/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7(9):1028-1034.
8. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor initiating cells. Proc Natl Acad Sci USA. 2010;107(8):3522-3527.
9. Moitra K, Lou H, Dear M. Multidrug efflux pumps and cancer stem cells: Insight into therapy resistance and therapeutic development. Clin Pharmacol Ther. 2011;89(4):491-502.
10. Frame FM, Maitland NJ. Cancer stem cells, model of study and implication of therapy resistance mechanisms. Adv Exp Med Biol. 2011;720(2):105-118.
11. Liau MC, Lin GW, Hurlbert RB. Partial purification and characterization of tumor and liver S-adenosylmethionine synthetases. Cancer Res. 1977;37(2):427-435.
12. Liau MC, Chang CF, Giovanella BC. Demonstration of an altered S-adenosyl-methionine synthetase in human malignant tumors xenografted into athymic nude mice. J Natl Cancer Inst. 1980;64(5):1071-1075.
13. Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Clin Oncol Cancer Res. 2010;7(2):86-96.
14. Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. Drug Exptl Clin Res. 1989;13(Suppl. 1):72-82.
15. Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. Nov Res Sci. 2021;7(2):1-3.
16. Liau MC, Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. In: Scicchitsano P, editor. New Horizons in Medicine and Medical Research. Vol. 6. 2022. p. 21-28.
17. Liau MC. Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof. US Patent. 2007;7233578 B2.
18. Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic cell differentiation agent formulation for the prevention and therapy of cancer via targeting of cancer stem cells. Cancer Stu Ther J. 2019;4(1):1-15.
19. Feng F, Li Q, Ling CQ, Zhang Y, Qin F, Wang H, et al. Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma. Chin J Clin Oncol. 2005;2(4):706-716.
20. Liau MC, Craig CL, Baker LL. CDA formulations: Potentially the standard care of breast, lung and liver cancers. Int J Clin Oncol Cancer Res. 2024;9(3):44-51.
21. Liau MC, Craig CL. On the mechanism of wound healing and the impact of wound on cancer evolution and cancer therapy. Int Res J Oncol. 2021;5(3):25-31.
22. Liau MC, Baker LL. Cancer arises as a consequence of wound not healing properly. Thus, perfection of wound healing must be the most appropriate strategy to win the war on cancer. Adv Complement Alt Med. 2021;6(3):584-586.
23. Liau MC, Baker LL. Wound healing, evolution of cancer and war on cancer. Int Res J Oncol. 2021;4(3):13-20.
24. Liau MC, Craig CL. No scar as an indication of perfect wound healing, ugly scar as imperfect wound healing and cancer as failed wound healing. J Cancer Tumor Intl. 2022;12(1):29-34.
25. Liau MC, Craig CL, Baker LL. Wound unhealing as a grave issue of cancer. Int Res J Oncol. 2023;6(1):97-103.
26. Liau MC, Fruehauf JP. The winner of the contest to eradicate cancer stem cells wins the contest of cancer therapies; The winner is cell differentiation agent formulations. Adv Complement Alt Med. 2020;5(4):476-478.
27. Liau MC, Fruehauf JP. Winning formulas to fulfill cancer moonshot. Int J Res Oncol. 2022;1(1):1-5.
28. Liau MC, Fruehauf JP. Cancer moonshot: Moonshot as a magic code to guide successful solution of tough challenges such as cancer. Int J Res Oncol. 2023;2(1):1-5.
29. Liau MC, Craig CL, Baker LL. CDA formulations to fulfill cancer moonshot and to win the war on cancer. Int J Res Oncol. 2023;2(2):1-8.
30. Liau MC. A perfect cancer drug must be able to take out both cancer cells and cancer stem cells, and to restore the functionality of chemo-surveillance. 3rd International Conference on Medicinal Chemistry and Drug Design, 13.
31. Liau MC, Baker LL. Destruction promotes the proliferation of progenitor stem cells and cancer stem cells and thus, non-destruction strategy is a better choice for cancer therapy. J Pharmacol Pharmaceu Pharmacovigi. 2020;4:029. DOI:10.24966/PPP-5649/100029.
32. Liau MC, Craig CL, Baker LL. Wound healing process as the most appropriate modality of cancer therapy. Eur J Applied Sci. 2023;11(1):463-471.
33. Liau MC, Craig CL, Baker LL. Wound healing process as the best strategy to save cancer patients. London J Med Health Res. 2023;23(13):1-11.
34. Liau MC, Craig CL, Baker LL. Healing the unhealed wound as the top priority to save cancer patients. Int J Res Oncol. 2025;4(1):1-10.
35. Liau MC. Abnormal methylation enzymes: A selective target for differentiation therapy of cancer. Chin Pharm J. 2004;56:57-67.
36. Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: The nature’s choice to win the war on cancer. Lambert Academic Publishing, 978-620-2-66889-7.
37. Liau MC, Baker LL. Abnormal methylation enzymes as the bullseye of targeted cancer therapy. Nov Res Sci. 2021;7(4):1-3.
38. Liau MC, Craig CL, Baker LL. Abnormal methylation enzymes as the most critical issue of cancer. Int Res J Oncol. 2023;6(2):168-176.
39. Liau MC, Craig CL, Baker LL. Exceptional allosteric regulation of methylation enzymes. In: Su S, editor. Novel Research Aspects in Medicine and Medical Research. Vol. 4. 2023. p. 39-56.
40. Liau MC, Fruehauf JP. Restoration of the chemo-surveillance capability is essential for the success of chemotherapy and radiotherapy to put cancer away. Adv Complement Alt Med. 2019;5(4):474-475.
41. Liau MC, Craig CL, Baker LL. Restoration of chemo-surveillance as a top priority to save cancer patients. Int Res J Oncol. 2023;6(2):227-237.
42. Liau MC, Craig CL, Baker LL. Elimination of cancer stem cells is essential to save cancer patients. Int J Res Oncol. 2024;3(1):1-9.
43. Liau MC, Craig CL, Baker LL. Destabilization of abnormal methylation enzymes as the only viable option for the elimination of cancer stem cells. Int Res Oncol. 2024;7(1):142-152.
44. Liau MC, Craig CL, Baker LL. Cell differentiation agents recommended for the rescue of metastatic, unresponsive and recurrent cancer patients. J Cancer Tumor Intl. 2024;14(2):28-37.
45. Liau MC, Craig CL, Baker LL. CDA formulations to make surgery a top choice of cancer therapy. Surgery Res J. 2024;4(3):1-8.
46. Liau MC, Craig CL, Baker LL. Healing the unhealed wounds as the top priority to save cancer patients. Int J Res Oncol. 2025;4(1):1-10.
47. Liau MC, Chang CF, Saunder GF, Tsai YH. S-Adenosylhomocysteine hydrolases as the primary target enzymes in androgen regulation of methylation complexes. Arch Biochem Biophys. 1981;208(1):261-272.
48. Liau MC, Baker LL. The impact of COVID-19 pandemic on cancer patients. Int Res J Oncol. 2022;6(4):13-17.
49. Liau MC, Liau CP, Burzynski SR. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Intl J Exptl Clin Chemother. 1992;5(1):9-17.
50. Liau MC, Huang L J, Lee JH, Chen SC, Kuo SC. Development of differentiation helper inducers for the differentiation therapy of cancer. Chin Pharm J. 1998;50(5):299-303.
51. Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. Bull Chin Cancer. 2002;11:166-168.
52. Liau MC, Kim JH, Fruehauf JP. Potentiation of ATRA activity in HLL-60 cells by targeting methylation enzymes. J Pharmacol Pharmaceu Pharmacovigi. 2019;3:009. DOI: 10.24966/PPP-5649/100009.
53. Liau MC, Szopa M, Burzynski B, Burzynski SR. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing Antineoplaston therapy. Drugs Exptl Clin Res. 1987;13(Suppl. 1):61-70.
54. Ma J. Differentiation therapy of malignant tumor and leukemia. CISCO Treaties on the Education of Clinical Oncology. 2007;480-486.
55. Liau MC, Chang CF, Becker FF. Alteration of S-adenosylmethionine synthetases during chemical hepatocarcinogenesis and in resulting carcinomas. Cancer Res. 1979;39:2113-2119.
56. Kamparath BN, Liau MC, Burzynski B, Burzynski SR. Protective effect of Antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1. Intl J Tiss React. 1979;12(Suppl.):43-50.
57. Virchow R. Die Cellular Pathologie in Ihrer Begrundung auf Physiologische and Pathologische Gewebelehave. Hirschwald. 1858;16:440.
58. Dvorack HF. Tumors: Wounds that do not heal. N Engl J Med. 1986;315(26):1650-1659.
59. MacCarthy-Morrough L, Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling. 2020;13:648.
60. Liau MC, Lee SS, Burzynski SR. Differentiation inducing components of Antineoplaston A5. Adv Expl Clin Chemother. 1988;6/88:9-26.
61. Liau MC, Burzynski SR. Separation of active anticancer components of Antineoplaston A2, A3 and A5. Intl J Tiss React. 1990;12(Suppl.):1-18.
62. Liau MC, Kim JH, Fruehauf JP. In pursuance of differentiation inducers to combat cancer via targeting of abnormal methylation enzymes. J Cancer Tumor Intl. 2019;10(2):39-47.
63. Liau MC, Kim JH, Fruehauf JP. Arachidonic acid and its metabolites as the surveillance differentiation inducers to protect healthy people from becoming cancer patients. Clin Pharmacol Toxicol Res. 2021;4(1):7-10.
64. Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. Intl J Exptl Clin Chemother. 1989;2:187-199.
65. Williamson PJ, Krugger AR, Reynolds PJ, Hamlin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndromes. Br J Haemato. 1994;87(4):743-745.
66. Boula A, Vougarelis M, Giannouli S, Katrinakis G, Psyllaki M, Pontikoglou C, et al. Effect of CA2 of antitumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res. 2006;12(10):3099-3108.
67. Itkin T, Rafii S. Leukemia cells “gas up” leaky bone marrow blood vessels. Cancer Cell. 2017;32(3):276-278.
68. Passarp D, Di Tullio A, Abarrategi A, Rousault-Pierre K, Foster K, Ariza-McNaughton L, et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell. 2017;32(3):324-341.
69. Woll PS, Kjallquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25(6):794-808.
70. Santi DV, Norment A, Carret CE. Covalent bond formation between DNA-cytosine methyltransferase of DNA containing 5-azacytosine. Proc Natl Acad Sci USA. 1984;81(22):6993-6997.
71. Prassana P, Shack S, Wilson VL, Samid D. Phenylacetate in chemoprevention of 5-aza-2’-deoxycytidine-induced carcinogenesis. Clin Cancer Res. 1995;1(18):865-871.
72. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumor in mice by genomic hypomethylation. Science. 2003;300(5618):489-492.
73. Palii SS, van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-aza-2’-deoxycytidine induces reversible DNA damage that is distinctly influenced by DNA-methyltransferase 1 and 3B. Mol Cell Biol. 2008;28(2):752-771.
74. Kizietepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, et al. 5-Azacytidine, a methyltransferase inhibitor, induces ATR-mediated DNA-double strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicine and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6(6):1718-1727.
75. Yang Q, Wu F, Wang F, Cai K, Zhang Y, Sun Q, et al. Impact of DNA methyltransferase inhibitor 5-azacytidine on cardiac development of zebrafish in vivo and cardiomyocyte proliferation, apoptosis, and the homeostasis of gene expression in vitro. J Cell Biochem. 2019;120(10):17459-17471.
76. Racanelli AC, Turner FB, Xie LY, Tayler SM, Moran RG. A mouse gene that coordinate epigenetic controls and transcriptional interference to achieve tissue specific expression. Mol Cell Biol. 2008;28(2):836-848.
77. Liau MC, Hunt ME, Hurlbert RB. Role of ribosomal RNA methylases in the regulation of ribosome production. Biochemistry. 1976;15(14):3158-3164.
78. Bernstein KA, Bleichert F, Bean JM, Cross FR, Baserga SJ. Ribosome biogenesis is sensed at the start cell cycle check point. Mol Biol Cell. 2007;18(3):953-964.
79. Justilien Y, Ali SA, Jamieson L, Yin N, Cox AD, Der CJ, et al. ECT2-dependent rRNA synthesis is required for KRAS-TRP53-driven lung adenocarcinoma. Cancer Cell. 2007;31(2):256-269.
80. Prudova A, Bauman Z, Braun A, Vitvitsky V, Lu SC, Banerjee R. S-Adenosyl-methionine stabilizes cystathionine beta-synthase and modulates redox capacity. Proc Natl Acad Sci USA. 2006;103(17):6489-6494.
81. Chiva P, Wallner C, Kaizer E. S-Adenosylmethionine metabolism in HL-60 cells: Effect of cell cycle and differentiation. Biochim Biophys Acta. 1988;971(1):38-45.
82. Huang M, Ye Y, Chen S, Chai JR, Wang ZY. Use of all trans-retinoic acid in the treatment of promyelocytic leukemia. Blood. 1988;72:567-572.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ming C Liau , Christine L Craig, Linda L Baker (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
